RxDoctor Payments Data

Emily Wright, APRN

Nurse Practitioner · Little Rock, ARNPI 1154960011

Payments from drug & device makers

$2,461in general payments, 2019–2025

Across 34 payments — averaging $72.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Teleflex LLC$555
  • Rochester Medical Corporation$247
  • Coloplast$111
  • Sumitomo Pharma America, Inc.$39
  • Boston Scientific$22
  • plus $16 from 1 others

What the payments were for

  • Travel & lodging$1,53762%
  • Food & beverage$92438%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.11$1,471
Teleflex LLC3$555
Rochester Medical Corporation14$247
Coloplast2$111
Sumitomo Pharma America, Inc.2$39
Boston Scientific1$22
Pfizer1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,461 in reported general payments places this provider in the 80th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$29,240
Medicare patients
205
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron48$23,821
MyrbetriqMirabegron22$13,551
VesicareSolifenacin Succinate13$4,406
Tamsulosin Hcl299$4,227
Trospium Chloride31$2,455
Estradiol28$2,036
Solifenacin Succinate40$1,861
Finasteride89$1,251
Oxybutynin Chloride ErOxybutynin Chloride53$1,204
Cephalexin64$518
Oxybutynin Chloride19$308
Alfuzosin Hcl ErAlfuzosin Hcl16$286
Doxazosin Mesylate16$250
NitrofurantoinNitrofurantoin Macrocrystal14$239
Testosterone Cypionate11$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$39$23,82148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →